Kelun-Biotech announces Phase III results for trastuzumab botidotin
Sichuan Kelun-Biotech said results from its Phase III registrational study of trastuzumab botidotin versus T-DM1 in HER2-positive breast cancer were published in the Journal of Clinical Oncology (JCO).
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.